Abstract: Objective：To detect the levels of serum chemerin in type 2 diabetic patients combined with metabolic syndrome (MS) and investigate the relationship between chemerin and interleukin-6 (IL-6). Methods：The clinical data of 108 newly diagnosed type 2 diabetic patients were analyzed, among which, 58 patients were assigned to the MS group and 50 patients were assigned to the nonMS group. Forty healthy patients during the same period were selected as the control group. The levels of serum chemerin, IL-6, fasting blood-glucose (FBG), glycosylated hemoglobin A1c (HbAlc), fasting insulin (FINS), and serum lipid were detected in three groups. Homeostasis model assessment of insulin resistance (HOMA-IR), body mass index (BMI) and waist-to-hip ratio (WHR) were calculated. Results：Serum chemerin level was significantly higher in MS group than that in nonMS group and control group (［77.2±9.2］ ng/mL vs［65.3±6.5］ ng/mL, ［77.2±9.2］ ng/mL vs［56.5±6.2］ ng/mL, P<0.05 and P<0.01, respectively). Compared with non-MS group and control group, the serum IL-6 level was significantly increased in MS group［48.8±6.4］ pg/mL vs［41.4±7.2］ pg/mL,［48.8±6.4］ pg/mL vs［32.7±4.9］pg/mL, P<0.01, respectively). Pearson correlation analysis showed that serum chemerin level was positively correlated with diastolic blood pressure, BMI, waist circumference, WHR, HOMA-IR, triglyceride (TG), and IL-6 (all P<0.05), and was negatively correlated with high-density lipoprotein cholesterol (HDL-C, P<0.01). Conclusions：Serum chemerin level is increased in type 2 diabetic patients with MS, and the level of serum chemerin is positively correlated with IL-6.